Rendering

Component: (Network and Table)
Network
100440 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Detail)
(http://www.acadia-pharm.com/20161231/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetail)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001070494 (http://www.sec.gov/CIK)
Income Tax Disclosure [Abstract]Period [Axis]
2016-12-31
2015-12-31
Income Tax Disclosure [Abstract]
 
 
NOL carryforwards
168,753,000  
161,277,000  
R&D credit carryforwards
21,016,000  
17,624,000  
Capitalized R&D
3,977,000  
4,901,000  
Stock-based compensation
27,576,000  
15,260,000  
Other
6,102,000  
2,126,000  
Deferred Tax Assets, Gross
227,424,000  
 
201,188,000  
 
Valuation allowance
(227,424,000) 
(201,188,000) 
Deferred Tax Assets, Net
0  
 
0